AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
HER2-CTC assay demonstrated high sensitivity and specificity in recent data
Non-invasive liquid biopsy enables repeated assessment of HER2 status
Parsortix system integration supports real-time monitoring of circulating tumor cells
The medical diagnostics sector, especially within oncology, is experiencing rapid evolution through liquid biopsy innovations. Companies in this space focus on developing methods to detect and monitor cancer biomarkers via simple blood draws. ANGLE PLC (LSE:AGL) has advanced its liquid-biopsy platform to address unmet needs in HER2-positive cancer care, leveraging proprietary technologies to capture and characterise circulating tumor cells.
New HER2-CTC Assay Findings
Recent presentations at a leading cancer-research conference detailed performance metrics for ANGLE’s experimental HER2-CTC blood test. Trial results showed accuracy well above ninety-eight percent in distinguishing HER2-positive circulating tumor cells from negative samples. Those findings underscore the assay’s capacity to identify HER2-overexpressing cells from peripheral blood, offering an alternative route to conventional tissue analysis. The company highlighted consistency across multiple test runs, underscoring assay robustness under controlled laboratory conditions.
Advantages over Tissue Biopsy
Traditional methods for determining HER2 expression rely on tissue samples obtained through invasive procedures. Those samples can fail to capture evolving tumor heterogeneity and carry procedural risks. The HER2-CTC blood test provides a minimally invasive procedure that can be repeated over the course of treatment. This approach addresses the dynamic nature of cancer, enabling clinicians to observe shifts in HER2 expression as therapy progresses. By reducing reliance on surgical biopsies, the test offers a more patient-friendly pathway to biomarker assessment.
Clinical Case Study Insights
Collaboration with BioView enabled the presentation of patient case reports illustrating the assay’s clinical relevance. In several instances, HER2-positive circulating tumor cells were detected in patients whose initial tissue tests had returned negative results. Those outcomes demonstrate the assay’s ability to uncover molecular changes missed by single time-point biopsies. Clinicians may leverage this information to refine therapeutic choices based on the most current disease profile, helping to align treatment approaches with real-time biomarker status.
Parsortix System Integration
The HER2-CTC assay depends on ANGLE’s proprietary Parsortix technology to isolate intact cells from a blood sample. Following capture, cells undergo immunofluorescence and fluorescent in situ hybridisation analyses to confirm HER2 gene amplification. This combination of physical separation and molecular characterisation supports high-confidence results. Laboratory teams reported consistent cell recovery and minimal sample handling, reinforcing the method’s suitability for adoption in clinical pathology workflows.
Toward Dynamic HER2 Monitoring
The latest data represent a significant step toward integrating real-time HER2-status evaluation into routine care. ANGLE’s blood-based assay bridges the gap between laboratory innovation and clinical application, offering the potential for more responsive treatment management. By enabling serial monitoring of circulating tumor cells, the approach equips medical teams with up-to-date insights on biomarker shifts, guiding more precise therapeutic interventions over the course of a patient’s journey.
